Pages with the most revisions

Jump to navigation Jump to search

Showing below up to 250 results in range #51 to #300.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

  1. Air-kerma, entrance surface‏‎ (5 revisions)
  2. Air-kerma, product‏‎ (4 revisions)
  3. Mass median diameter‏‎ (4 revisions)
  4. Fractionation sensitivity‏‎ (4 revisions)
  5. Math‏‎ (4 revisions)
  6. Programmed cell death‏‎ (4 revisions)
  7. Air kerma at the patient entrance reference point‏‎ (4 revisions)
  8. High linear energy transfer radiation‏‎ (4 revisions)
  9. Reference Animal and Plant‏‎ (4 revisions)
  10. Kp index‏‎ (4 revisions)
  11. Bioassay‏‎ (4 revisions)
  12. Calculating Radon Doses‏‎ (4 revisions)
  13. Computed tomography dose index‏‎ (4 revisions)
  14. Protective action‏‎ (4 revisions)
  15. Direct bioassay‏‎ (4 revisions - redirect page)
  16. Alpha decay‏‎ (4 revisions)
  17. Effective charge number‏‎ (4 revisions)
  18. Source-related assessment‏‎ (4 revisions)
  19. Reference bioassay function‏‎ (4 revisions)
  20. Risk‏‎ (4 revisions)
  21. Senescence‏‎ (4 revisions)
  22. Effective half-life‏‎ (4 revisions)
  23. Averted dose‏‎ (4 revisions)
  24. Optimisation‏‎ (4 revisions)
  25. Sievert‏‎ (4 revisions)
  26. S coefficient (radiation weighted)‏‎ (4 revisions)
  27. Forbiddenness‏‎ (4 revisions)
  28. Aerodynamic diameter‏‎ (4 revisions)
  29. ICRP‏‎ (4 revisions)
  30. Non-maleficence‏‎ (4 revisions)
  31. Diagnostic reference level‏‎ (4 revisions)
  32. Fractionation‏‎ (3 revisions)
  33. Organ dose equivalent‏‎ (3 revisions)
  34. Active (red) bone marrow‏‎ (3 revisions)
  35. Granulocyte-macrophage colony-stimulating factor‏‎ (3 revisions)
  36. Recovery‏‎ (3 revisions)
  37. Granulocyte colony-stimulating factor‏‎ (3 revisions)
  38. Spread-out Bragg peak‏‎ (3 revisions)
  39. Coster-Kronig transition‏‎ (3 revisions)
  40. Emergency preparedness‏‎ (3 revisions)
  41. Gray‏‎ (3 revisions)
  42. Wisdom‏‎ (3 revisions)
  43. Emergency procedures‏‎ (3 revisions)
  44. Absolute risk‏‎ (3 revisions)
  45. Auger transition‏‎ (3 revisions)
  46. Target region‏‎ (3 revisions)
  47. Bystander effect‏‎ (3 revisions)
  48. Employer‏‎ (3 revisions)
  49. Activity median thermodynamic diameter‏‎ (3 revisions)
  50. Complex tissues‏‎ (3 revisions)
  51. Derived air concentration‏‎ (3 revisions)
  52. Dignity‏‎ (3 revisions)
  53. Growth fraction‏‎ (3 revisions)
  54. Potential exposure‏‎ (3 revisions)
  55. Excretion rate (instantaneous)‏‎ (3 revisions)
  56. Rigidity threshold‏‎ (3 revisions)
  57. Extrathoracic airways‏‎ (3 revisions)
  58. Galactic cosmic radiation‏‎ (3 revisions)
  59. Growth hormone (somatotropin)‏‎ (3 revisions)
  60. Low Earth orbit‏‎ (3 revisions)
  61. ICRP Publication 103‏‎ (3 revisions)
  62. X ray‏‎ (3 revisions)
  63. Fairness‏‎ (3 revisions)
  64. Absorption‏‎ (3 revisions)
  65. Gamma ray‏‎ (3 revisions)
  66. Unsealed source‏‎ (3 revisions)
  67. Xerostomia‏‎ (3 revisions)
  68. DNA damage signalling‏‎ (3 revisions)
  69. Dose equivalent‏‎ (3 revisions)
  70. Field-size effect (Volume effect)‏‎ (3 revisions)
  71. Gastrointestinal syndrome‏‎ (3 revisions)
  72. Interphase death‏‎ (3 revisions)
  73. Test‏‎ (3 revisions)
  74. Biomedical research volunteer‏‎ (3 revisions)
  75. Cardiomyopathy‏‎ (3 revisions)
  76. Public exposure‏‎ (3 revisions)
  77. Dose limit‏‎ (3 revisions)
  78. Flexible tissues‏‎ (3 revisions)
  79. Guide to the System of Radiological Protection‏‎ (3 revisions)
  80. Autonomy‏‎ (3 revisions)
  81. Uptake‏‎ (3 revisions)
  82. Dose limits‏‎ (3 revisions)
  83. Fluence‏‎ (3 revisions)
  84. Utilitarian ethics‏‎ (3 revisions)
  85. Operational quantity‏‎ (3 revisions)
  86. Constancy test‏‎ (3 revisions)
  87. Dose‏‎ (3 revisions)
  88. Fluoroscopically guided interventions‏‎ (3 revisions)
  89. Annual dose‏‎ (3 revisions)
  90. Value judgement‏‎ (3 revisions)
  91. DS02‏‎ (3 revisions)
  92. Dose of record (E)‏‎ (3 revisions)
  93. Accountability‏‎ (3 revisions)
  94. Half-life, physical‏‎ (3 revisions)
  95. Cell death‏‎ (3 revisions)
  96. Valvular heart disease‏‎ (3 revisions)
  97. Contamination‏‎ (3 revisions)
  98. Personal dose equivalent‏‎ (3 revisions)
  99. Principle of justification‏‎ (3 revisions)
  100. Radiofrequency ablation‏‎ (3 revisions)
  101. Exponential survival curve‏‎ (3 revisions)
  102. Iso-effect plots‏‎ (3 revisions)
  103. Annual limit on intake‏‎ (3 revisions)
  104. Lifetime risk estimates‏‎ (3 revisions)
  105. Virtue ethics‏‎ (3 revisions)
  106. Radiological Protection in Healthcare‏‎ (3 revisions - redirect page)
  107. Dose per content function‏‎ (3 revisions)
  108. Equity‏‎ (3 revisions)
  109. Graded approach‏‎ (3 revisions)
  110. Isomers‏‎ (3 revisions)
  111. Voxel phantom‏‎ (3 revisions)
  112. Dose per unit intake coefficient‏‎ (2 revisions)
  113. Emergency‏‎ (2 revisions)
  114. Reproductive integrity‏‎ (2 revisions)
  115. Exposure, external or internal‏‎ (2 revisions)
  116. Safety case‏‎ (2 revisions)
  117. Slow repair‏‎ (2 revisions)
  118. Graft vs host disease‏‎ (2 revisions)
  119. Air-kerma, incident‏‎ (2 revisions)
  120. Isotropic geometry‏‎ (2 revisions)
  121. Heliosphere‏‎ (2 revisions)
  122. Lineal energy‏‎ (2 revisions)
  123. Thyroid blocking‏‎ (2 revisions)
  124. Transparency‏‎ (2 revisions)
  125. Class SR-0 gases‏‎ (2 revisions)
  126. Waste disposal‏‎ (2 revisions)
  127. Non-targeted effects‏‎ (2 revisions)
  128. Decontamination‏‎ (2 revisions)
  129. Procedural values‏‎ (2 revisions)
  130. Diastasis‏‎ (2 revisions)
  131. Dose rate‏‎ (2 revisions)
  132. Reasonableness‏‎ (2 revisions)
  133. Emergency exposure situation‏‎ (2 revisions)
  134. Erythropoietin‏‎ (2 revisions)
  135. Residual dose‏‎ (2 revisions)
  136. Exposure (in the context of inhalation)‏‎ (2 revisions)
  137. Safety culture‏‎ (2 revisions)
  138. Fractionation and dose delivery patterns‏‎ (2 revisions)
  139. Solar cosmic radiation‏‎ (2 revisions)
  140. Inhalability‏‎ (2 revisions)
  141. Spontaneous fission‏‎ (2 revisions)
  142. Itinerant (radiation) worker‏‎ (2 revisions)
  143. Linear-non-threshold model‏‎ (2 revisions)
  144. Broad beam therapy irradiation technique‏‎ (2 revisions)
  145. Trapped particles‏‎ (2 revisions)
  146. Class SR-1 gases‏‎ (2 revisions)
  147. Committed effective dose‏‎ (2 revisions)
  148. Orphan source‏‎ (2 revisions)
  149. Cost-benefit analysis‏‎ (2 revisions)
  150. Planned exposure situation‏‎ (2 revisions)
  151. Decontamination factor‏‎ (2 revisions)
  152. Progenitor cell‏‎ (2 revisions)
  153. Radiation belt‏‎ (2 revisions - redirect page)
  154. Radiological protection principles‏‎ (2 revisions)
  155. Dose rate effectiveness factor‏‎ (2 revisions)
  156. Emergency plan‏‎ (2 revisions)
  157. Ethics‏‎ (2 revisions)
  158. Respiratory protection‏‎ (2 revisions)
  159. ALARA‏‎ (2 revisions)
  160. Scintigraphy‏‎ (2 revisions)
  161. Solar cycle‏‎ (2 revisions)
  162. Inner bremsstrahlung‏‎ (2 revisions)
  163. Hierarchical tissues‏‎ (2 revisions)
  164. Area monitoring‏‎ (2 revisions)
  165. Systemic model‏‎ (2 revisions)
  166. Linear-quadratic dose response model‏‎ (2 revisions)
  167. Benthic‏‎ (2 revisions)
  168. Time factor‏‎ (2 revisions)
  169. Bronchial region‏‎ (2 revisions)
  170. Myocardial perfusion‏‎ (2 revisions)
  171. Class SR-2 gases‏‎ (2 revisions)
  172. What is Radon?‏‎ (2 revisions)
  173. Committed equivalent dose‏‎ (2 revisions)
  174. Platelet-derived growth factor‏‎ (2 revisions)
  175. Dichotomous‏‎ (2 revisions)
  176. Radiation modifier‏‎ (2 revisions)
  177. Radionuclides of natural origin‏‎ (2 revisions)
  178. Recovery (cellular or tissue)‏‎ (2 revisions)
  179. Retrievability‏‎ (2 revisions)
  180. Immune system‏‎ (2 revisions)
  181. Activity‏‎ (2 revisions)
  182. Institutional control‏‎ (2 revisions)
  183. Stakeholder‏‎ (2 revisions)
  184. High level waste‏‎ (2 revisions)
  185. Tachycardia‏‎ (2 revisions)
  186. Tissue equivalent material‏‎ (2 revisions)
  187. Myocardial stress test‏‎ (2 revisions)
  188. Clearance‏‎ (2 revisions)
  189. Oversight‏‎ (2 revisions)
  190. Deontological Ethics‏‎ (2 revisions)
  191. Projected dose‏‎ (2 revisions)
  192. Differentiation‏‎ (2 revisions)
  193. Dose constraint‏‎ (2 revisions)
  194. Radioresponsiveness‏‎ (2 revisions)
  195. Early normal tissue responses‏‎ (2 revisions)
  196. Recovery responder‏‎ (2 revisions)
  197. Reversibility‏‎ (2 revisions)
  198. In vivo radiobioassay‏‎ (2 revisions)
  199. Solar particle event‏‎ (2 revisions)
  200. Beta-minus decay‏‎ (2 revisions)
  201. Clearance level‏‎ (2 revisions)
  202. Worker‏‎ (2 revisions)
  203. Nuclear track detectors‏‎ (2 revisions)
  204. Radiation safety officer‏‎ (2 revisions)
  205. Dose conversion coefficient‏‎ (2 revisions)
  206. Radiosensitiser‏‎ (2 revisions)
  207. Edema‏‎ (2 revisions)
  208. Rehabilitation of living conditions‏‎ (2 revisions)
  209. Excess relative risk‏‎ (2 revisions)
  210. Right to know‏‎ (2 revisions)
  211. Exposure situation‏‎ (2 revisions)
  212. Incidence‏‎ (2 revisions)
  213. Solar wind‏‎ (2 revisions)
  214. Growth factor‏‎ (2 revisions)
  215. Alimentary tract transfer factor‏‎ (2 revisions)
  216. Target tissue‏‎ (2 revisions)
  217. Beta-plus decay‏‎ (2 revisions)
  218. Measuring and Reducing Radon Levels in your Home‏‎ (2 revisions)
  219. Calculating Doses from Intakes of Radionuclides‏‎ (2 revisions)
  220. Working level‏‎ (2 revisions)
  221. OLINDA/EXM‏‎ (2 revisions)
  222. Particle radiance‏‎ (2 revisions)
  223. Cumulative dose‏‎ (2 revisions)
  224. Protection strategy‏‎ (2 revisions)
  225. Radiation source‏‎ (2 revisions)
  226. Radiosensitivity, cellular‏‎ (2 revisions)
  227. Effect Dose 50‏‎ (2 revisions)
  228. Endogeneous excretion‏‎ (2 revisions)
  229. Rigidity‏‎ (2 revisions)
  230. Exposure to Radon at Home‏‎ (2 revisions)
  231. Security‏‎ (2 revisions)
  232. Incident‏‎ (2 revisions)
  233. GATA binding protein 2‏‎ (2 revisions)
  234. Intermediate level waste‏‎ (2 revisions)
  235. Stenosis‏‎ (2 revisions)
  236. Hormones‏‎ (2 revisions)
  237. Authorization‏‎ (2 revisions)
  238. Local DRL‏‎ (2 revisions)
  239. Tolerability‏‎ (2 revisions)
  240. Medical exposure‏‎ (2 revisions)
  241. Naturally occurring radioactive material‏‎ (2 revisions)
  242. Clonogenic cells‏‎ (2 revisions)
  243. Working level month‏‎ (2 revisions)
  244. Curie‏‎ (2 revisions)
  245. Inclusiveness‏‎ (2 revisions)
  246. Acute radiation syndrome‏‎ (2 revisions)
  247. Source-related‏‎ (2 revisions)
  248. Internal conversion electron‏‎ (2 revisions)
  249. LD 50/30‏‎ (2 revisions)
  250. Hounsfield unit‏‎ (2 revisions)

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)